1004 related articles for article (PubMed ID: 9647550)
41. The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium.
Roopa BA; Loganath A; Singh K
Hum Reprod; 2003 Sep; 18(9):1809-19. PubMed ID: 12923132
[TBL] [Abstract][Full Text] [Related]
42. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
Modesto W; Bahamondes MV; Bahamondes L
Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
[TBL] [Abstract][Full Text] [Related]
43. Effects of the levonorgestrel intrauterine system on the endometrium after long-term exposure to mifepristone: Secondary outcomes of a randomized controlled trial.
Papaikonomou K; Frisendahl C; Williams ARW; Gemzell-Danielsson K
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():330-335. PubMed ID: 32653606
[TBL] [Abstract][Full Text] [Related]
44. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient.
Fong YF; Singh K
Contraception; 1999 Jul; 60(1):51-3. PubMed ID: 10549453
[TBL] [Abstract][Full Text] [Related]
45. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
[TBL] [Abstract][Full Text] [Related]
46. Endometrial vasculature in Norplant users.
Rogers PA
Hum Reprod; 1996 Oct; 11 Suppl 2():45-50. PubMed ID: 8982745
[TBL] [Abstract][Full Text] [Related]
47. The influence of the levonorgestrel-releasing intrauterine system position on bleeding patterns in reproductive age women.
Alves RDMS; Rabelo MM; Andrade VR; Cabral RCS; Merriman JW; Brito MB
Int J Gynaecol Obstet; 2019 Dec; 147(3):326-331. PubMed ID: 31489621
[TBL] [Abstract][Full Text] [Related]
48. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
[TBL] [Abstract][Full Text] [Related]
49. The levonorgestrel intrauterine system in the management of menorrhagia.
Barrington JW; Bowen-Simpkins P
Br J Obstet Gynaecol; 1997 May; 104(5):614-6. PubMed ID: 9166207
[TBL] [Abstract][Full Text] [Related]
50. Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
Stéphanie R; Labied S; Blacher S; Frankenne F; Munaut C; Fridman V; Beliard A; Foidart JM; Nisolle M
Hum Reprod; 2007 Dec; 22(12):3084-91. PubMed ID: 17921480
[TBL] [Abstract][Full Text] [Related]
51. Vascular effect of levonorgestrel intrauterine system on heavy menstrual bleeding: is it associated with hemodynamic changes in uterine, radial, and spiral arteries?
Şahin H; Güngören A; Sezgin B; Ün B; Şahin EA; Dolapçioğlu K; Bayik RN
J Obstet Gynaecol; 2021 Jan; 41(1):89-93. PubMed ID: 32573299
[TBL] [Abstract][Full Text] [Related]
52. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
53. A review of the endometrial changes in Norplant users.
Wan LS
Ann N Y Acad Sci; 1997 Sep; 828():108-10. PubMed ID: 9329828
[TBL] [Abstract][Full Text] [Related]
54. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
55. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
Hidalgo MM; Hidalgo-Regina C; Bahamondes MV; Monteiro I; Petta CA; Bahamondes L
Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
[TBL] [Abstract][Full Text] [Related]
56. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users.
Lau TM; Witjaksono J; Affandi B; Rogers PA
Hum Reprod; 1996 Dec; 11(12):2629-34. PubMed ID: 9021364
[TBL] [Abstract][Full Text] [Related]
57. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia.
Qi X; Zhao W; Duan Y; Li Y
Gynecol Obstet Invest; 2008; 65(4):266-8. PubMed ID: 18196936
[TBL] [Abstract][Full Text] [Related]
58. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
Rose S; Chaudhari A; Peterson CM
Adv Drug Deliv Rev; 2009 Aug; 61(10):808-12. PubMed ID: 19445984
[TBL] [Abstract][Full Text] [Related]
59. The levonorgestrel-releasing intrauterine device.
Toivonen J
Adv Contracept Deliv Syst; 1994; 10(3-4):191-8. PubMed ID: 12287838
[TBL] [Abstract][Full Text] [Related]
60. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception.
Jones RL; Salamonsen LA; Critchley HO; Rogers PA; Affandi B; Findlay JK
Mol Hum Reprod; 2000 Dec; 6(12):1107-17. PubMed ID: 11101694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
